Who We Are

At BridgePoint Life Sciences, we believe exceptional patient care starts with smarter commercialization strategies. Our founders bring decades of experience in hospital system leadership and the biopharma industry, blending inside knowledge of how providers, payers, and policies interact to shape patient access.

We specialize in the most complex challenges facing rare and specialty therapies:

  • Launch Strategy – end-to-end planning across pricing, distribution, and HEOR

  • Payer Engagement – unmatched expertise in value-based contracting, including the first-ever U.S. VBA for a therapy, as well as pioneering cell and gene therapy agreements

  • Hospital & IDN Access – navigating formulary pathways, 340B, inpatient/outpatient reimbursement, and specialty pharmacy integration, provide cell and gene therapy onboarding direction and support

  • Channel & Distribution Strategy – optimizing models across specialty pharmacy, buy-and-bill, and direct-to-site logistics, managing complex cell and gene therapy logistics

  • Provider-Payer Alignment – mapping early adopters and their payer mix to accelerate uptake

Every engagement is grounded in our patient-first values, ensuring that innovative therapies don’t just launch they reach the people who need them most.

What sets BridgePoint apart is our ability to integrate payer, provider, and policy perspectives into access strategies that are clinically sound, financially viable, and operationally executable.